Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials (Dermatology and Therapy, (2024), 14, 8, (2235-2248), 10.1007/s13555-024-01224-x) Dermatology and Therapy April 2025;15(4):1037-1044

Date

04/01/2025

DOI

10.1007/s13555-024-01317-7

Scopus ID

2-s2.0-105000008313 (requires institutional sign-in at Scopus site)

Author

Kenneth Brian Gordon MD Professor in the Dermatology department at Medical College of Wisconsin